Answers are grounded in this paper and cite their sources.
Objective: The goal of this study was to show the clinical characteristics, tolerability, safety and outcomes of geriatric patients treated with dalbavancin. Materials and Methods:A retrospective and observational study was conducted in a tertiary-level hospital.All patients over 80 years old who received at least one dose of dalbavancin from June 2016 to December 2021 were in included.Demographic and clinical data, microbiological, indication for dalbavancin prescription, adverse effects and evolution of the infection were collected in this study.Geriatric assessment of the patient on admission was also documented, including Barthel Index and the presence of polypharmacy in their treatments.Results: A total of 25 patients were included (mean age=87), mostly were female (64%), coming from their usual residence (72%), independent for the activities of daily living "ADLs" (68%) and in a hyperpolypharmacy regimen (up to 44%).Fourteen patients presented endovascular infections like endocarditis/ vascular device infections (53%), the other 13 patients (47%) debuted with locomotor system infections such as joint prosthetic infection or septic arthritis.Regarding the microbiological data, 56% of the patients were infected by streptococcus/enterococcus group, followed by methicillin-resistant coagulase-negative staphylococci (24%) and methicillin-resistant S. aureus (20%).No patient experienced adverse effects.Conclusion: Dalbavancin is presented as an attractive antibiotic in the geriatric population due to its potential uses in complex pathologies, showing safety and efficacy in short treatments or in prolonged regimens.
No takes yet. Share an insight, caveat, or question.
Sastre et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: